None listed
Conditions
Interventions
Dietary Supplement : Participants will be randomly assigned to either the test group or the control group and will consume the test food or control food once daily for 4 weeks. One tablet will be take
Sponsors
Hecto Healthcare
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Adults aged 19 to 70 years at the time of screening. 2) Participants with a score of =2 on the organoleptic test for halitosis. 3) Participants with hydrogen sulfide (H2S) levels of =112 ppb and methyl mercaptan (CH3SH) levels of =26 ppb. 4) Participants who agree not to undergo periodontal treatment during the study period. 5) Participants who voluntarily provide written informed consent to participate in the study and are able to understand and comply with the study procedures.
Exclusion criteria
Exclusion criteria: 1) Participants who have undergone scaling within 3 months or periodontal treatment within 6 months prior to the screening visit, or who are expected to require dental treatment during the study period. 2) Participants who are currently receiving treatment for or have a history of the following conditions (however, participation may be permitted at the discretion of the Principal Investigator based on the participant's clinical condition): ?Uncontrolled systemic diseases that may affect halitosis ?Untreated severe dental diseases ?Uncontrolled hypertension ?Uncontrolled diabetes mellitus or current insulin therapy ?Active upper respiratory tract disease ?Active or symptomatic gastrointestinal disease ?Psychiatric disorders 3) Participants who have taken any of the following medications, health functional foods, or foods within 2 weeks prior to the screening visit: ?Medications that may affect the oral microbiota ?Medications that reduce salivary secretion ?Psychotropic medications ?Sodium-glucose cotransporter-2 (SGLT2) inhibitors ?Products containing the same or similar ingredients as the investigational product 4) Participants who have taken any of the following medications, health functional foods, or foods within 1 week prior to the screening visit: ?Systemic medications that may affect halitosis ?Products intended to alleviate halitosis 5) Participants currently using inhaled bronchodilators or inhaled corticosteroids. 6) Participants with known hypersensitivity, allergy, or adverse reactions to any ingredients contained in the investigational product or control product. 7) Participants who have participated in another clinical trial or human study within the previous 3 months, or who plan to participate in another study during the study period (participants in observational studies involving no administration of drugs or foods [e.g., injection, ingestion, or insertion] are eligible). 8) Participants who are pregnant or breastfeeding, or who plan to become pregnant during the study period. 9) Participants with a history of drug abuse or suspected drug dependence. 10) Participants who work night shifts or have irregular bedtime schedules due to occupational or other reasons. 11) Participants with excessive alcohol consumption. 12) Heavy smokers. 13) Participants whom the Principal Investigator considers unsuitable for participation based on clinical laboratory test results or any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Oral volatile sulfur compound (VSC) concentrations | — |
Secondary
| Measure | Time frame |
|---|---|
| Tongue coating index;Plaque index;Oral microbiota;Subjective improvement of halitosis;Halitosis-related discomfort questionnaire;Matrix metalloproteinases;Safety assessments | — |
Countries
Korea, Republic of
Contacts
Public ContactYENA LEE
Hallym University Medical Center
Outcome results
None listed